Risk Factors for Mortality among HIV-Infected Patients with Disseminated Histoplasmosis

• Main Authors: Mathieu Nacher, Kinan Drak Alsibai, Audrey Valdes, Romain Blaizot, Philippe Abboud, Magalie Demar, Félix Djossou, Loïc Epelboin, Caroline Misslin, Balthazar Ntab, Antoine Adenis, Pierre Couppié
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Journal of Fungi
• Subjects: disseminated histoplasmosis; HIV; mortality; risk factors; liposomal amphotericin B; French Guiana
• Online Access: https://www.mdpi.com/2309-608X/6/4/326

Identifying prognostic factors is important in order to guide the choice of first-line therapy for disseminated histoplasmosis. Our objective was to identify factors associated with death among a cohort of 330 patients compiled over 34 years of clinical practice in French Guiana. Survival analysis was performed with death as the failure event and date of symptom onset as the origin event. Incidence rates were and Cox proportional hazards models were computed. Overall, 330 HIV-infected patients with disseminated histoplasmosis were included in the analysis, with 126 deaths occurring. One-quarter of all patients died within 6 months of the first symptoms. Patients with dyspnea, renal failure, arterial blood pressure < 90 mmHG, and a WHO performance score > 2 had a greater incidence of death. Bivariate analyses showed that patients with increased LDH, low hemoglobin, low serum protein, low CD4 counts, and low platelets tended to have a greater incidence of death. After adjusting for potential confounders, patients with dyspnea, a WHO performance score > 2, serum protein < 60 g/L, and hemoglobin < 8.9 g/dL had an increased risk of dying. The interaction terms showed that patients treated with liposomal amphotericin B had a marked reduction in death among patients with renal failure; among renal failure patients, the elevation of LDH was associated with a significant risk of death.